What is Amylyx Pharmaceuticals's earnings per share (EPS)?

Amylyx Pharmaceuticals (AMLX) reported diluted earnings per share of $-1.53 for fiscal year 2025. This represents a 65.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Amylyx Pharmaceuticals Financials

AMLX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Amylyx Pharmaceuticals (AMLX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

Amylyx Pharmaceuticals's revenue declined 100% year-over-year, from $87.4M to $0. This contraction results in a growth score of 0/100.

Leverage

100

Amylyx Pharmaceuticals carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 14.27, Amylyx Pharmaceuticals holds $14.27 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Amylyx Pharmaceuticals generates a -47.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -183.1% the prior year.

Piotroski F-Score Weak

3/9

Amylyx Pharmaceuticals passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.85x

For every $1 of reported earnings, Amylyx Pharmaceuticals generates $0.85 in operating cash flow (-$123.3M OCF vs -$144.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

Amylyx Pharmaceuticals generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

-$152.8M

YoY+51.3%

Amylyx Pharmaceuticals's EBITDA was -$152.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 51.3% from the prior year.

Net Income

-$144.7M

YoY+52.0%

Amylyx Pharmaceuticals reported -$144.7M in net income in fiscal year 2025. This represents an increase of 52.0% from the prior year.

EPS (Diluted)

$-1.53

YoY+65.5%

Amylyx Pharmaceuticals earned $-1.53 per diluted share (EPS) in fiscal year 2025. This represents an increase of 65.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$123.5M

YoY+26.4%

Amylyx Pharmaceuticals generated -$123.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 26.4% from the prior year.

Cash & Debt

$226.7M

YoY+192.9%

Amylyx Pharmaceuticals held $226.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

110M

YoY+60.1%

Amylyx Pharmaceuticals had 110M shares outstanding in fiscal year 2025. This represents an increase of 60.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-47.4%

YoY+135.7pp

Amylyx Pharmaceuticals's ROE was -47.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 135.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$90.4M

YoY-13.1%

Amylyx Pharmaceuticals invested $90.4M in research and development in fiscal year 2025. This represents a decrease of 13.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$138K

YoY-12.1%

Amylyx Pharmaceuticals invested $138K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 12.1% from the prior year.

AMLX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$0-100.0%	$87.4M-77.1%	$380.8M+1612.9%	$22.2M+7700.0%	$285K
Cost of Revenue	$0-100.0%	$6.0M-76.6%	$25.4M+750.0%	$3.0M	N/A
Gross Profit	$0-100.0%	$81.4M-77.1%	$355.3M+1747.2%	$19.2M	N/A
R&D Expenses	$90.4M-13.1%	$104.1M-18.8%	$128.2M+37.2%	$93.5M+112.2%	$44.0M
SG&A Expenses	$62.9M-45.0%	$114.3M-39.3%	$188.4M+48.2%	$127.1M+226.5%	$38.9M
Operating Income	-$153.3M+51.3%	-$314.7M-911.1%	$38.8M+119.3%	-$201.3M-143.5%	-$82.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A
Income Tax	$46K+111.7%	-$393K-107.8%	$5.0M+549.4%	$774K	N/A
Net Income	-$144.7M+52.0%	-$301.7M-712.4%	$49.3M+124.8%	-$198.4M-125.6%	-$87.9M
EPS (Diluted)	$-1.53+65.5%	$-4.43-732.9%	$0.70+120.6%	$-3.39+74.6%	$-13.35

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	$0	$0	$0	N/A	$416K	N/A	$88.6M
Cost of Revenue	N/A	$0	$0	$0	N/A	$0-100.0%	$8K-99.9%	$5.9M
Gross Profit	N/A	$0	$0	$0	N/A	$416K+140.3%	-$1.0M-101.2%	$82.7M
R&D Expenses	N/A	$19.9M-27.0%	$27.2M+23.0%	$22.1M	N/A	$21.2M-9.0%	$23.3M-36.2%	$36.6M
SG&A Expenses	N/A	$16.2M+3.4%	$15.6M-0.3%	$15.7M	N/A	$17.8M-17.6%	$21.6M-62.5%	$57.8M
Operating Income	N/A	-$36.0M+15.9%	-$42.9M-13.4%	-$37.8M	N/A	-$75.7M+0.8%	-$76.3M+37.5%	-$122.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	N/A	$0	$0-100.0%	$242K
Net Income	N/A	-$34.4M+17.0%	-$41.4M-15.4%	-$35.9M	N/A	-$72.7M0.0%	-$72.7M+38.8%	-$118.8M
EPS (Diluted)	N/A	$-0.37+19.6%	$-0.46-9.5%	$-0.42	N/A	$-1.070.0%	$-1.07+38.9%	$-1.75

AMLX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$332.6M+71.8%	$193.6M-62.6%	$517.5M+32.2%	$391.5M+270.6%	$105.6M
Current Assets	$323.7M+70.9%	$189.4M-59.2%	$464.7M+21.6%	$382.1M+264.1%	$105.0M
Cash & Equivalents	$226.7M+192.9%	$77.4M-54.5%	$170.2M+172.2%	$62.5M+24.6%	$50.2M
Inventory	N/A	$0-100.0%	$38.3M+292.3%	$9.8M	N/A
Accounts Receivable	$88K-80.3%	$447K-98.9%	$40.0M+161.7%	$15.3M	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$27.4M-5.1%	$28.9M-65.6%	$84.0M+65.2%	$50.8M-80.2%	$256.8M
Current Liabilities	$22.7M-20.1%	$28.4M-65.4%	$82.0M+76.0%	$46.6M+167.9%	$17.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$305.3M+85.3%	$164.8M-62.0%	$433.4M+27.3%	$340.6M+325.3%	-$151.2M
Retained Earnings	-$751.4M-23.9%	-$606.7M-98.9%	-$304.9M+13.9%	-$354.2M-127.3%	-$155.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$332.6M-8.3%	$362.7M+86.4%	$194.6M-11.4%	$219.7M+13.4%	$193.6M-22.8%	$250.7M-24.5%	$332.2M-20.4%	$417.5M
Current Assets	$323.7M-8.4%	$353.4M+89.1%	$186.9M-13.5%	$216.1M+14.1%	$189.4M-22.8%	$245.3M-24.9%	$326.7M-20.4%	$410.5M
Cash & Equivalents	$226.7M+0.7%	$225.2M+287.7%	$58.1M-2.8%	$59.8M-22.8%	$77.4M+7.7%	$71.8M-4.2%	$75.0M-56.0%	$170.6M
Inventory	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A
Accounts Receivable	$88K-33.3%	$132K+28.2%	$103K-65.7%	$300K-32.9%	$447K-74.2%	$1.7M-57.7%	$4.1M-79.9%	$20.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$27.4M-10.9%	$30.7M+15.1%	$26.7M+46.3%	$18.3M-36.8%	$28.9M-47.0%	$54.5M-23.1%	$70.9M-23.8%	$93.0M
Current Liabilities	$22.7M-12.0%	$25.8M+20.4%	$21.4M+19.5%	$17.9M-36.9%	$28.4M-47.3%	$53.9M-23.1%	$70.1M-23.5%	$91.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$305.3M-8.1%	$332.0M+97.8%	$167.9M-16.7%	$201.4M+22.2%	$164.8M-16.0%	$196.2M-24.9%	$261.3M-19.5%	$324.4M
Retained Earnings	-$751.4M-4.6%	-$718.4M-5.0%	-$684.0M-6.4%	-$642.6M-5.9%	-$606.7M-6.6%	-$569.1M-14.6%	-$496.4M-17.2%	-$423.7M

AMLX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$123.3M+26.4%	-$167.6M-1506.6%	$11.9M+106.6%	-$179.9M-140.5%	-$74.8M
Capital Expenditures	$138K-12.1%	$157K-87.3%	$1.2M-50.9%	$2.5M+615.6%	$353K
Free Cash Flow	-$123.5M+26.4%	-$167.8M-1671.5%	$10.7M+105.9%	-$182.4M-142.7%	-$75.2M
Investing Cash Flow	$14.0M-81.4%	$75.7M-17.8%	$92.1M+138.5%	-$239.0M-415.0%	-$46.4M
Financing Cash Flow	$257.0M+73758.9%	$348K-90.2%	$3.5M-99.2%	$431.8M+172.4%	$158.5M
Dividends Paid	$0	$0	$0	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$27.9M+8.1%	-$30.4M-20.3%	-$25.2M+36.6%	-$39.8M	N/A	-$41.6M+37.6%	-$66.6M-13515.5%	-$489K
Capital Expenditures	$86K+258.3%	$24K+41.2%	$17K+54.5%	$11K	N/A	-$19K-121.3%	$89K+32.8%	$67K
Free Cash Flow	-$28.0M+7.9%	-$30.4M-20.3%	-$25.3M+36.6%	-$39.8M	N/A	-$41.6M+37.6%	-$66.7M-11890.8%	-$556K
Investing Cash Flow	$29.5M+462.8%	$5.2M-77.2%	$23.0M+152.7%	-$43.7M	N/A	$38.8M+234.0%	-$29.0M-3636.1%	$819K
Financing Cash Flow	-$208K-100.1%	$191.6M+618183.9%	-$31K-100.0%	$65.7M	N/A	$80K+196.3%	$27K-79.4%	$131K
Dividends Paid	$0	$0	$0	$0	N/A	$0	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AMLX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	93.2%-0.1pp	93.3%+6.8pp	86.5%	N/A
Operating Margin	N/A	-360.2%-370.4pp	10.2%+915.9pp	-905.7%+28107.6pp	-29013.3%
Net Margin	N/A	-345.4%-358.3pp	12.9%+905.3pp	-892.4%+29960.6pp	-30853.0%
Return on Equity	-47.4%+135.7pp	-183.1%-194.5pp	11.4%+69.6pp	-58.2%	N/A
Return on Assets	-43.5%+112.3pp	-155.8%-165.3pp	9.5%+60.2pp	-50.7%+32.6pp	-83.3%
Current Ratio	14.27+7.6	6.67+1.0	5.66-2.5	8.20+2.2	6.03
Debt-to-Equity	0.09-0.1	0.18-0.0	0.19+0.0	0.15+1.8	-1.70
FCF Margin	N/A	-192.1%-194.9pp	2.8%+823.3pp	-820.5%+25548.6pp	-26369.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	100.0%	N/A	93.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-18187.7%	N/A	-137.8%
Net Margin	N/A	N/A	N/A	N/A	N/A	-17476.9%	N/A	-134.0%
Return on Equity	N/A	-10.4%+14.3pp	-24.7%-6.9pp	-17.8%	N/A	-37.1%-9.2pp	-27.8%+8.8pp	-36.6%
Return on Assets	N/A	-9.5%+11.8pp	-21.3%-4.9pp	-16.4%	N/A	-29.0%-7.1pp	-21.9%+6.6pp	-28.5%
Current Ratio	14.27+0.6	13.70+5.0	8.72-3.3	12.05+5.4	6.67+2.1	4.55-0.1	4.66+0.2	4.48
Debt-to-Equity	0.090.0	0.09-0.1	0.16+0.1	0.09-0.1	0.18-0.1	0.280.0	0.27-0.0	0.29
FCF Margin	N/A	N/A	N/A	N/A	N/A	-9997.4%	N/A	-0.6%

Similar Companies

Stoke Therapeutics STOK

$1.9B

Tourmaline Bio TRML

$1.2B

Dianthus Therapeutics Inc DNTH

$4.4B

LENZ THERAPEUTICS INC LENZ

$286.9M

Xeris Biopharma Holdings XERS

$1.0B

Frequently Asked Questions

What is Amylyx Pharmaceuticals's annual revenue?

Amylyx Pharmaceuticals (AMLX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Amylyx Pharmaceuticals's revenue growing?

Amylyx Pharmaceuticals (AMLX) revenue declined by 100% year-over-year, from $87.4M to $0 in fiscal year 2025.

Is Amylyx Pharmaceuticals profitable?

No, Amylyx Pharmaceuticals (AMLX) reported a net income of -$144.7M in fiscal year 2025.

What is Amylyx Pharmaceuticals's EBITDA?

Amylyx Pharmaceuticals (AMLX) had EBITDA of -$152.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Amylyx Pharmaceuticals's return on equity (ROE)?

Amylyx Pharmaceuticals (AMLX) has a return on equity of -47.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Amylyx Pharmaceuticals's free cash flow?

Amylyx Pharmaceuticals (AMLX) generated -$123.5M in free cash flow during fiscal year 2025. This represents a 26.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Amylyx Pharmaceuticals's operating cash flow?

Amylyx Pharmaceuticals (AMLX) generated -$123.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Amylyx Pharmaceuticals's total assets?

Amylyx Pharmaceuticals (AMLX) had $332.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Amylyx Pharmaceuticals's capital expenditures?

Amylyx Pharmaceuticals (AMLX) invested $138K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Amylyx Pharmaceuticals spend on research and development?

Amylyx Pharmaceuticals (AMLX) invested $90.4M in research and development during fiscal year 2025.

How many shares does Amylyx Pharmaceuticals have outstanding?

Amylyx Pharmaceuticals (AMLX) had 110M shares outstanding as of fiscal year 2025.

What is Amylyx Pharmaceuticals's current ratio?

Amylyx Pharmaceuticals (AMLX) had a current ratio of 14.27 as of fiscal year 2025, which is generally considered healthy.

What is Amylyx Pharmaceuticals's debt-to-equity ratio?

Amylyx Pharmaceuticals (AMLX) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Amylyx Pharmaceuticals's return on assets (ROA)?

Amylyx Pharmaceuticals (AMLX) had a return on assets of -43.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Amylyx Pharmaceuticals's cash runway?

Based on fiscal year 2025 data, Amylyx Pharmaceuticals (AMLX) had $226.7M in cash against an annual operating cash burn of $123.3M. This gives an estimated cash runway of approximately 22 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Amylyx Pharmaceuticals's Piotroski F-Score?

Amylyx Pharmaceuticals (AMLX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Amylyx Pharmaceuticals's earnings high quality?

Amylyx Pharmaceuticals (AMLX) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (AMLX) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.